Osteopontin (OPN) is a secreted, integrin-binding glycophosphoprotein that has been implicated in breast cancer. We previously showed that OPN-induced cell migration of mammary epithelial cells (MEC) depends on binding to cell surface integrins and involves activation of the hepatocyte growth factor (HGF) receptor, Met. Here, we show that OPN-induced migration of MEC also requires activation of the epidermal growth factor (EGF) pathway. Synergism was seen between EGF and OPN in inducing cell migration. Furthermore, incubation of cells with exogenous OPN increased ligand (TGFa>EGF) and EGF receptor (EGFR) mRNA expression, as well as EGFR kinase activity. Treatment of cells with anti-TGFa or anti-EGFR antibody, or with tyrphostin-25 (EGFR inhibitor), significantly impaired the cell migration response to OPN. Other more broad-spectrum tyrosine kinase inhibitors and the growth factor/ receptor interaction inhibitor, suramin, also inhibited OPN-induced migration. Using specific signal transduction pathway inhibitors, we have screened for involvement of MEK (MAP kinase kinase), phosphatidylinositol 3-kinase, phospholipase C (PLC), and protein kinase C (PKC). Results implicated all of these pathways in OPN-induced cell migration, the most pronounced effect being seen with PLC and PKC inhibitors. These results suggest that induction of MEC migration by OPN involves a cascade of events including at least two growth factor/receptor pathways and multiple downstream signal transduction pathways. A number of potential targets are thus provided for strategies aimed at blocking the malignancy-promoting effects of OPN.
Introduction
Osteopontin (OPN) is a secreted, integrin-binding glycophosphoprotein whose levels are increased in primary tumors and plasma of patients with breast cancer (Brown et al., 1994; Bellahce`ne and Castronovo, 1995; Hirota et al., 1995; Singhal et al., 1997; Senger et al., 1988; Tuck et al., 1998) . Our clinical studies have shown a relationship between tumor cell OPN and prognosis in patients with lymph node-negative breast cancer (Tuck et al., 1998) , as well as between plasma OPN, tumor burden, and prognosis in patients with metastatic breast cancer (Singhal et al., 1997) . Given the accumulating evidence for a clinical association between OPN levels and malignancy of breast cancer, we have undertaken studies to determine the functional role for OPN in inducing malignancy of breast cancer cells. We previously showed that OPN induces cell migration (Tuck et al., 2000) and invasion (Tuck et al., 1999) of mammary epithelial cells (MEC) in culture. We also showed that OPN-induced cell migration depends on different integrin receptors for cells of differing malignancy (21PT, 21NT, MDA-MB-435), and that the migration response for all these cell lines involves activation of the HGF receptor, Met (Tuck et al., 2000) .
Although HGF receptor is activated in these cells in response to OPN, we have seen incomplete inhibition of OPN-induced cell migration using anti-HGF functionblocking antibody. As activation of epidermal growth factor receptor (EGFR) has also been shown to influence migration of mammary epithelial cells (reviewed in Wells, 1999 Wells, , 2000 , we have here examined whether EGFR may be involved in OPN responsiveness as well. For these studies, we have made use of three cell lines of differing malignancy: 21PT (nontumorigenic), 21NT (tumorigenic, nonmetastatic) (Band et al., 1990) , and MDA-MB-435 (tumorigenic, metastatic) (Price et al., 1990) . We found that OPN and exogenously added EGF are indeed complementary in inducing migration of all three cell lines. Upon incubation of all three cell lines with OPN, upregulation of EGFR mRNA expression and protein kinase activity was seen. In addition, mRNA expression levels of two major EGFR ligands (TGFa and EGF) were assessed following induction with OPN. 21PT and 21NT cells showed a marked increase in TGFa expression, and all three cell lines showed a marginal increase in EGF expression. Function-blocking anti-TGFa and anti-EGFR antibodies were used to demonstrate the dependency of the OPN-induced migration response on EGFR activation. That the tyrosine kinase activity of EGFR is required for OPN-induced cell migration was also demonstrated by inhibition with tyrphostin-25. Finally, to screen for the possible pathways involved in OPN-induced cell migration response, we used a panel of inhibitors aimed at different levels of the signal transduction process, including a growth factor/receptor interaction inhibitor (suramin), broad-spectrum tyrosine kinase inhibitors (genistein, herbimycin), and inhibitors of MEK (PD98059), PI 3-kinase (PI3K) (wortmannin), PLC (U73122), and PKC (calphostin). All of these inhibitors impaired OPN-induced cell migration, with the most pronounced effect being seen with the PLC and PKC inhibitors.
Results
Effect of OPN and EGF, alone and in combination, on cell migration All three cell lines (21PT, 21NT, MDA-MB-435) showed significant increase in cell migration in transwell assays, in response to either OPN or EGF alone, over that of BSA controls (Po0.05 for all) (Figure 1 ). Incubation with OPN and EGF together resulted in a complementary effect on cell migration, again for all three cell lines (Po0.01 for all) (Figure 1 ). Cell migration in the presence of both OPN and EGF was more than the sum of the effects of OPN or EGF alone, suggesting a synergistic relationship. 
Induction of

EGFR kinase assay and Western blotting
Incubation with OPN resulted in induction of EGFR kinase activity in all three cell lines ( Figure 3 ). For 21PT cells, increase in EGFR kinase activity was seen by 30 min, whereas for 21NT and MDA-MB-435 cells, increased activity was not detected until 5 h of incubation. The EGFR kinase response of MDA-MB-435 was short-lived, having fallen off (to below baseline levels) by 18 h. No significant change in EGFR protein level (as determined by Western blotting) was observed for any of the three cell lines, either in the presence or absence of OPN induction, after up to 18 h of incubation (not shown).
EGFR pathway dependence of OPN-induced cell migration
Transwell migration experiments for all three cell lines showed significant inhibition of OPN-induced cell migration with anti-TGFa or anti-EGFR blocking antibodies (Po0.05 for all, Figures 4 and 5, respectively). Inhibition of EGFR kinase activity with tyrphostin-25 resulted in significant inhibition of migration of 21PT and 21NT cells as early as 5 h incubation (Po0.001 for both), and of MDA-MB-435 cells after 18 h incubation (Po0.001) (Figure 6 ).
Signal transduction pathway inhibitors and OPN-induced cell migration
Signal transduction pathway inhibitors tested for activity in blocking OPN-induced cell migration included: the growth factor/receptor interaction inhibitor (suramin), tyrosine kinase inhibitors (tyrphostin-25, herbimycin A, genistein), MEK inhibitor (PD98059), PI3 K inhibitor (wortmannin), PLC inhibitor (U73122), and PKC inhibitor (calphostin C). All of these agents were found to significantly inhibit OPN-induced cell migration of all three cell lines, the most pronounced effect being seen with the PLC and PKC inhibitors (Po0.05 for all, Figure 7 ). In all cases, these effects were seen with negligible cell toxicity (>95% cell viability by trypan blue dye exclusion). As mentioned above, the blocking effect of tyrphostin-25 on OPN-induced 
Discussion
In recent years, it has become apparent that many different integrin-induced cellular responses involve collaborative interaction with growth factor/receptor pathways (reviewed in Schwartz, 1997; Giancotti and Ruoslahti, 1999; Schwartz and Ginsberg, 2002) . One level of this interaction is seen in the induction of phosphorylation of either HGF receptor (Met) (e.g. Wang et al., 1996; Qiao et al., 2000; Tuck et al., 2000) or EGF receptor (e.g. Miyamoto et al., 1996; Wang et al., 1998; Lee and Juliano, 2002; Moro et al., 2002) by cell adhesion/integrin activation. However, convergence of signaling between these pathways most likely occurs further downstream as well (Giancotti and Ruoslahti, 1999; Schwartz and Ginsberg, 2002) , and the nature of the interactions is expected to be cell type-and integrinspecific in many instances.
In exploring the malignancy-promoting effects of OPN on mammary epithelial cells, we have previously shown OPN-induced cell migration to be integrin dependent, and have implicated different integrins in cell lines of low (21PT, 21NT) vs high (MDA-MB-435) malignancy (Tuck et al., 2000) . Specifically, OPNinduced cell migration of 21PT and 21NT cells involves avb5 and b1, whereas MDA-MB-435 cells respond via avb3. Taking the results of that previous study along with the work performed here, we now know that although they use different cell surface integrins to respond to OPN, all three of these cell lines also show complementarity in effect between OPN and both HGF and EGF in induction of cell migration, MDA-MB-435 (using avb3) showing the greatest synergy of effect. In addition, we have observed that tyrosine kinase activity of both Met and EGFR indeed increases upon induction by OPN. These results are in keeping with those reported using other systems, in which integrin activation has been shown to increase sensitivity to growth factor ligand (Miyamoto et al., 1996; Schneller et al., 1997; Soldi et al., 1999) , and to increase tyrosine phosphorylation/activation of the receptor (Miyamoto et al., 1996; Wang et al., 1996; Jones et al., 1997; Moro et al., 2002) . Interestingly, in the case of EGFR activation, Moro et al. (2002) have shown that integrins may induce phosphorylation of different tyrosine residues of EGFR than that induced by EGF, suggesting the possibility of different levels of control of receptor activity.
Although in the case of HGF/Met we did not see significant effect of OPN on ligand (HGF) expression (Tuck et al., 2000) , here we found that OPN can increase TGFa mRNA in 21PT and 21NT, and marginally 
OPN-induced migration involves EGFR AB Tuck et al
We have here demonstrated the involvement of EGFR in OPN-induced migration of 21PT, 21NT, and MDA-MB-435 cells by experiments using anti-EGFR antibody or the EGFR kinase inhibitor, tyrphostin-25, to block this effect. All three cell lines showed significant inhibition of OPN-induced migration with either anti-EGFR or tyrphostin-25 treatment. The fact that MDA-MB-435 required overnight incubation to achieve full effect of tyrphostin-25 may be a reflection of the lower number of target sites (lower EGFR expression), as well as involvement of other EGFR family members (e.g. Adelsman et al., 1999) in OPN responsiveness of these cells.
The findings here are proof in principle that anti-EGFR interventions can be useful in inhibiting malignancy-promoting effects of OPN on breast cancer cells, at least in terms of OPN-induced cell migration.
As alluded to above, there is evidence in the literature for convergence of integrin and growth factor receptor signaling pathways at multiple levels. Overlap of influence (integrin vs growth factor receptormediated) may be seen in at least three major pathways; PLC/PKC, MAPK, and PI3 K (review in Schwartz, 1997) . By virtue of its binding to av integrins, and in turn activating growth factor receptors (Met and EGFR), OPN could potentially influence any or all of these pathways (Sodek et al., 2000; Furger et al., 2001; Tuck and Chambers, 2001 ). In order to determine which of these possible pathways may be critical to OPN-induced migratory behavior, we have examined the effect of a panel of inhibitors that interfere at different levels, from growth factor interaction with receptor (suramin), to tyrosine kinase activity of receptor (genestein, herbimycin A), to MAP kinase kinase (MEK, inhibitor PD98059), PI3 K (wortmannin), and PLC/PKC (U73122, calphostin C) activity inhibition. All of these agents were found to significantly inhibit OPN-induced migration, in all cases with minimal cell toxicity, thus implicating all of these pathways in some aspect of signaling in response to OPN. The most pronounced effect was seen with PLC and PKC inhibitors. As the PLC/PKC pathway has been shown to mediate signals via both EGFR and Met (Comoglio, 1993; Kassis et al., 1999; Price et al., 1999; Kermorgant et al., 2001) , this may again reflect the importance of growth factor receptor pathway activation in the migration response to OPN.
It is thus clear that the integrin-dependent induction of cell migration of MEC by OPN involves, and is dependent upon the activation of at least two different growth factor/receptor pathways (EGF ligands/EGFR and HGF/Met), and multiple different signal transduction pathways. Although the network of signaling in response to OPN appears from the inhibitor studies to be complex, it provides a multiplicity of potential targets for intervention aimed at blocking the malignancypromoting effects of OPN.
Materials and methods
Cell lines and culture
The 21 T series cell lines (21PT, 21NT) were obtained as a kind gift from Dr Vimla Band (Dana Farber Cancer Institute) (Band et al., 1990) . MDA-MB-435 cells were obtained as a kind gift from Dr Janet Price (MD Anderson Cancer Center, Houston, TX, USA). Culture conditions were as previously described (Tuck et al., 1999) .
RNA isolation and Northern blot analysis
Cell pellets from subconfluent monolayers were mechanically homogenized (Polytron PT 1200, Brinkman Instruments (Canada) Ltd, Mississauga, ON, Canada) and RNA extracted using TRIzol Reagent (Canadian Life Technologies Inc., Burlington, ON), according to the protocol supplied by the manufacturer. RNA (10 mg/lane) was run on a 1.1% agarose gel with 6.8% formaldehyde and capillary-transferred to GeneScreen Plus filters (DuPont Canada Inc., Mississauga, ON, Canada). Blots were probed either with denatured, oligolabeled [ 32 P] dCTP cDNA probes (labeled using a kit provided by Pharmacia, Baie d'Urfe, PQ), or with 5 0 [g 32 P] ATP end-labeled oligomers (labeled using a kit provided by Oncogene Science, Manhasset, NY, USA), according to the procedures provided by the manufacturers, and as previously described (Tuck et al., 1990 (Tuck et al., , 1991 .
Probes used included TGFa (40 base antisense oligonucleotide derived from sequences encoding the mature human TGFa polypeptide, Derynck et al. (1984) , Cedarlane), EGF (0.555 kb EcoRI fragment of human EGF cDNA plasmid phEGF121, containing the 5 0 untranslated region and encoding amino acids 1-38 of the EGF precursor, Murray et al., 1986, ATCC) , and EGFR (1.65 kb ClaI-EcoRI fragment of human EGF receptor cDNA, Xu et al., 1984) . Even loading of lanes was confirmed by probing blots with a human 18S rRNA probe (p100D9; a kind gift from Dr DT Denhardt).
Cell migration
Cell migration assays were performed essentially as described previously (Xuan et al., 1995; Tuck et al., 2000) , using 24-well transwell chambers with polycarbonate filters of 8 mm pore size (Costar, Cambridge, MA), coated with gelatin at 6 mg/filter. The assays were performed over 5 h, as determined by preliminary time course experiments. Lower wells contained 800 ml of aHE plus 0.1% BSA, with or without OPN, EGF, and/or blocking antibody or inhibitor, as specified. (While EGF has been shown to be required for continued culture of 21PT and 21NT cells (Band et al., 1990) , we have found that there is no detectable change in proliferation of these cells during the first 24 h after EGF deprivation (data not shown).) Human OPN (50 mg/ml) used was the full-length human recombinant GST-OPN (hrOPN), as previously described (Xuan et al., 1994) . Previous control experiments have shown that the GST portion alone has no influence on the migration of these cells. Human recombinant EGF (20 ng/ml) was obtained from GIBCO-BRL/Life Technologies. Blocking antibodies included anti-TGFa (Ab-3 from Cedarlane, Hornby, ON, USA) and anti-EGFR (Ab-1 from Cedarlane). For antibody blocking experiments, controls were also performed in which blocking antibody in the lower chamber was replaced by nonimmune mouse IgG at comparable concentration (Tuck et al., 2000) . Inhibitors included tyrphostin-25, suramin, herbimycin A, genistein, PD98059, U73122, calphostin C, and wortmannin (all from Sigma). Inhibitor concentrations were chosen to give optimum effect with >95% cell viability (as determined by trypan blue dye exclusion).
All cell migration and invasion assays were performed in triplicate. Statistical differences between groups were assessed using the Mann-Whitney test, t-test, or ANOVA, using SigmaStat (Jandel Scientific, San Rafael, CA, USA) statistical software.
In vitro EGFR kinase assay
In vitro EGFR kinase assays were performed essentially as described by Donato et al. (1989) . Cells in monolayer were grown to 85-90% confluence, serum starved overnight, and incubated in serum-free medium either with or without human OPN (50 mg/ml) for the times specified. Cells were then rinsed with cold PBS, and lysed in lysis buffer containing 50 mm Tris-HCL (pH 7.5), 150 mm NaCl, 1% NP-40, 1 mm Na 3 VO 4 , 50 mm NaF, 2 mm EGTA, 2 mg/ml aprotinin, 2 mg/ml leupeptin, and 1 mm PMSF. Lysates were centrifuged for 10 min at 14 000 r.p.m. in an IEC/Micromax centrifuge at 41C. Protein concentration of supernatants was determined using the BioRad protein assay (GIBCO-BRL/Life Technologies, Grand Island, NY, USA). Equal protein amounts of each lysate were immunoprecipitated with anti-human EGFR monoclonal antibody (Ab-1 from Cedarlane) at 41C for 2 h.
Immunoprecipitates were collected on protein A-Sepharose (Amersham-Pharmacia Biotech, Baie d'Urfe, Quebec), washed twice with cold lysis buffer and once with cold kinase buffer (20 mm PIPES, pH 7.0, 10 mm MnCl 2 , 10 mm Na 3 VO 4 ). In vitro EGFR kinase activity was determined by incubating immunoprecipitates with 20 ml of kinase buffer containing 10 mCi [g-32 P]ATP at 301C for 10 min. The reaction was stopped by addition of 2X SDS sample buffer containing 5% bmercaptoethanol. Samples were boiled for 3 min, spun in a microfuge for 15 s at 16 000 g and subjected to 7% SDS-PAGE. Serine and threonine phosphorylations were hydrolyzed by incubating the acrylamide gel in 1 m KOH at 451C for 30 min, followed by fixing in 10% MeOH and 7.5% acetic acid for 30 min at room temperature, and drying for 2 h at 801C under a vaccum. Autoradiograms were produced and quantitated using a Storm Phosphorimager (Molecular Dynamics, Sunnyvale, CA, USA).
Western Blotting for EGFR protein
Immunoprecipitates prepared as above, were collected on protein A-Sepharose (Amersham-Pharmacia Biotech), washed three times with lysis buffer, separated by 7% SDS-PAGE, and transferred to a nitrocellulose membrane. The membrane was blocked for 15 min with 1% BSA in TBST (10 mm Tris-HCL, pH 8.0, 150 mm NaCl, 0.1% Tween 20) and probed for 1 h with polyclonal rabbit anti-human EGFR (1005, Santa Cruz Biotech, Santa Cruz, CA, USA). The membrane was washed three times for 5 min each with TBST buffer, incubated with horseradish peroxidase-labeled secondary anti-rabbit antibody (Amersham-Pharmacia Biotech) for 15 min, and washed three times with TBST for 10 min each. Immune complexes were detected using ECL (Amersham-Pharmacia Biotech.).
